Chronic Kidney Disease (Stage 3-4)
10
4
4
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
10%
1 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (10)
Screening for Cardiac and Cardiac-associated Pathology Using Single-channel Electrocardiogram
Safety and Efficacy of SC101 Via Perirenal Fat Injection for Resistant Hypertension in Patients With Moderate to Severe Chronic Kidney Disease
Prospective AnalysiS of Self medIcation With phytOtherapy in Nephropatic Patients.
Phosphate Assessment in Chronic Kidney Disease Patients Study
Effect Of Education On Adherence, Self Care And Well-Being Of Patients With Chronic Kidney Disease
AK+ Guard™ Pilot Study in Chronic Kidney Disease: Outpatient Diagnostic Accuracy and Remote Monitoring
Equol and Vascular Function in Women With Chronic Kidney Disease
ACE Reno, Pico Cell Matrix and Its Effect on eGFR in Chronic Kidney Diseases
Outcome of Use of a Novel Modulator of Oxidative Phosphorylation on Kidney Function in Patients With Progressive Chronic Kidney Disease
Effects of Aerobic Versus Resistance Training on Bone Metabolism in Stage 3-4 Chronic Kidney Disease